Found: 2
Select item for more details and to access through your institution.
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 2, p. 217, doi. 10.1111/apt.17764
- By:
- Publication type:
- Article
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.
- Published in:
- Journal of Clinical & Translational Hepatology, 2024, v. 12, n. 5, p. 469, doi. 10.14218/JCTH.2023.00417
- By:
- Publication type:
- Article